WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
-15.01%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$1.48B
AUM Growth
+$1.48B
(-32%)
Cap. Flow
-$326M
Cap. Flow
% of AUM
-22%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
4
Reduced
2
Closed
1
Top Buys
| 1 |
Alkermes
ALKS
|
$13.7M |
| 2 |
Prothena Corp
PRTA
|
$6.71M |
| 3 |
Biogen
BIIB
|
$3.34M |
| 4 |
Theravance Biopharma
TBPH
|
$1.14M |
Top Sells
| 1 |
AbbVie
ABBV
|
$344M |
| 2 |
Gilead Sciences
GILD
|
$6.18M |
| 3 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$647K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Prothena Corp
PRTA
$441M
| $432M | 29.14% | 11,528,614 +179,000 | +2% | +$6.71M |
|
|
2
Alkermes
ALKS
$4.78B
| $415M | 27.99% | 7,585,683 +250,000 | +3% | +$13.7M |
|
|
3
Theravance Biopharma
TBPH
$699M
| $300M | 20.21% | 10,747,108 +41,000 | +0.4% | +$1.14M |
|
|
4
Biogen
BIIB
$19.4B
| $118M | 7.96% | 370,564 +10,480 | +3% | +$3.34M |
|
|
5
Gilead Sciences
GILD
$140B
| $113M | 7.63% | 1,579,353 -86,239 | -5% | -$6.18M |
|
|
BIVV
6
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $105M | 7.08% | 1,948,325 -12,000 | -0.6% | -$647K |
|
|
7
AbbVie
ABBV
$372B
| – | – | -3,875,358 | Closed | -$344M |
|